Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triaminic Allerchews

This article was originally published in The Tan Sheet

Executive Summary

Upcoming late January launch of 10 mg loratadine quick-dissolve, wintergreen-flavored tablets under Triaminic children's cough/cold line may provide Novartis Consumer Healthcare's OTC unit with a strong start to 2004 sales. Triaminic Allerchews will debut in 8- and 24-count packages with substantial consumer and trade promotion support, Novartis says. The product will compete against Schering-Plough's Claritin Children's Formula Syrup, which contains 5 mg loratadine per dose (1"The Tan Sheet" July 28, 2003, p. 11)...
Advertisement

Related Content

Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”
Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2
Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2

Topics

Advertisement
UsernamePublicRestriction

Register

PS096386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel